Compare Novavax Inc (NVAX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares UltraPro QQQ ETF — how do they compare? Novavax Inc trades at $7.95 (market cap $1.31B), while ProShares UltraPro QQQ ETF trades at $74.85. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | TQQQ | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.19 | $87.22 |
52-Week Low | $6.22 | $37.89 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
TQQQ trades at $74.61, up 1.12% with a bullish technical signal from moving averages. The leveraged ETF benefits from strong Nasdaq-100 performance and AI-driven tech momentum. Recent institutional buying by Bay Colony Advisory Group and positive earnings from hyperscalers support current levels. However, the RSI at 74 suggests potential overbought conditions near key resistance at $75.
Outlook remains positive given tech sector strength, but volatility decay and leverage risks require careful position sizing. The ETF's structural costs compound daily, making it better suited for tactical rather than long-term holdings. Current momentum favors continued upside if tech earnings maintain strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
